Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | triple-receptor negative breast cancer | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-355) that supported FDA approval, addition of Keytruda (pembrolizumab) to chemotherapy significantly improved progression-free survival compared to chemotherapy alone (9.7 vs 5.6, HR=0.65, p=0.0012) in patients with locally recurrent or metastatic triple-receptor negative breast cancer expressing CD274 (PD-L1, CPS>=10), as determined by an FDA-approved test (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1000-1000; NCT02819518). | detail... detail... detail... |
CD274 positive | triple-receptor negative breast cancer | sensitive | Pembrolizumab | Guideline | Actionable | The combination of Keytruda (pembrolizumab) plus chemotherapy such as Taxol (paclitaxel), Abraxane (nab-paclitaxel), or Paraplatin (carboplatin) plus Gemzar (gemcitabine) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). | detail... 34678411 |
PubMed Id | Reference Title | Details |
---|---|---|
ESMO Clinical Practice Guidelines | Full reference... | |
Full reference... | ||
Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. | Full reference... | |
(34678411) | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. | Full reference... |